Summary: Marksans Pharma signed a share purchase agreement to acquire a 100% stake in Access Healthcare for Medical Products L.L.C, a Dubai-based…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Tag:
Biopharmaceutical
-
-
Daiichi SankyoRegulatoryU.S FDA
FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki(Enhertu) for Breast Cancer
by adminby adminSummary: Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive breast cancer…
-
Merger / Acquisition
Lilly Pumps $700M into Boston-Based RNA Therapeutics Facility
by adminby adminSummary: Eli Lilly and Company is investing $700 million to build a state-of-the-art facility in Boston’s seaport as part of plans to…
-
Bristol Myers SquibbCompaniesMerck & CoMerger / Acquisition
BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform with 2.3 Billion Collab
by adminby adminSummary : Bristol Myers Squibb and Merck KGaA are diving deeper into the protein degradation pool, with both inking partnerships with Amphista Therapeutics…
-
RegulatoryU.S FDA
Supernus Announces FDA Approval of Qelbree®(Viloxazine) for the Treatment of ADHD in Adults
by adminby adminSummary : Qelbree (i.e. SPN-812) is a nonstimulant ADHD medication containing a serotonin norepinephrine modulating agent approved by the FDA to treat attention deficit…
-
Bristol Myers SquibbRegulatoryU.S FDA
BMS Scores FDA Approval for Novel HCM Treatment Camzyos (Mavacamten)
by adminby adminSummary : Camzyos (mavacamten), the first FDA-approved cardiac myosin inhibitor that directly addresses the root of obstructive hypertrophic cardiomyopathy, has been authorised…
-
CompaniesEuropeEurope Medicine Agency (EMA)Pfizer
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First ever Marketing Authorization by European Commission for both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
by adminby adminSummary : Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing…
-
Summary : HYFTOR™ is the first topical treatment approved by the FDA for facial angiofibroma in individuals with tuberous sclerosis complex (TSC) 6…
-
Summary : The Venus VivaTM will now make its American premiere, having already established itself as a pioneer in the worldwide medical…
-
Global MarketRegulatoryU.S FDA
Sol-Gel Technologies and Galderma’s EPSOLAY® Scores US FDA Approval
by adminby adminSummary: EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent…